secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001493152-25-005100
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma presents preclinical data on KROS 101 at AACR-JCA; shows tumor reduction in melanoma models
--------------------------------------------------------------------------------

- KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.
- In a preclinical study, KROS 101 reduced melanoma tumor in human GITR knock-in mouse model vs. the GITR antibody TRX518.
- Data presented at the 13th AACR-JCA Joint Conference from Feb 1-5, 2025 in Maui, Hawaii.
- CEO Dr. John S. Yu and VP R&D Dr. Ramachandran Murali co-presented; potential for melanoma and glioblastoma therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225005100/0001493152-25-005100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225005100/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer